Kruppel-like factor 4 (KLF4) is a transcription factor that is highly expressed in differentiated epithelial cells including that of the skin. It is critical for specification or function of differentiated epithelial cells. Moreover, KLF4 functions either as a tumor suppressor or an oncogene depending on different cellular contexts. However, the role of KLF4 in skin tumorigenesis remains controversial. To address this issue, we first examined KLF4 expression using a cohort of samples from patients with skin squamous cell carcinoma and basal cell carcinoma and found that in 21 of 24 tumor tissues (87.5%), KLF4 expression as assayed by immunohistochemistry was absent when compared with that in normal tissues. In addition, knockdown of KLF4 in human epidermal squamous cell carcinoma SCC13 cells was accompanied by increased cell growth. Further analysis revealed that KLF4 deficiency promoted cell migration and adhesion, which are the important properties of tumor cells. These observations were supported by the effect upon overexpression of KLF4 in SCC13 cells. Furthermore, we generated a novel tamoxifen-inducible KLF4/CreER and KLF4(flox) double transgenic mouse model to examine the role of KLF4 in skin cancer development. Consistent with in vitro studies, KLF4 deficiency increased the ability of migration and adhesion of mouse primary skin keratinocytes. Moreover, KLF4 knockout led to increased cell proliferation and skin carcinogenesis in a classical DMBA/ TPA mouse skin cancer model. Taken together, our data suggest that KLF4 inhibits cell proliferation, migration and adhesion and that loss of KLF4 promotes skin tumorigenesis.
Introduction
Kruppel-like factor 4 (KLF4) as a member of the Kruppel-like factor (KLF) family is a zinc finger containing transcription factor expressed in a wide range of tissues in mammals, such as the gastrointestinal tract and the skin (1) (2) (3) . It plays a critical role in regulating diverse array of cellular processes including proliferation, differentiation, development, maintenance of normal tissue homeostasis and apoptosis (4, 5) . At a molecular level, KLF4 regulates expression of many genes, such as CDKN1A (p21), cyclin D1 and cyclin B, which are involved in regulation of cell cycle progression resulting in cell cycle arrest at both the G 1 -S and G 2 -M transition points and inhibition of cell proliferation (6) (7) (8) (9) (10) . In addition, KLF4 has been shown to have key functions in stem cell biology, as evidenced by inhibiting embryonic stem cells differentiation (11) , by increasing their self-renewal capacity (12) , by inducing induced pluripotent stem cells (13) and by maintaining breast cancer stem cells (14) .
Previous mouse studies suggest that KLF4 is critical in specification or function of differentiating epithelial cells. KLF4 null mice die from dehydration shortly after birth, due to loss of skin barrier function without morphological and biochemical alterations to the well-known structural features of epidermis that are essential for mechanical integrity. Instead, knockout of KLF4 selectively perturbs the differentiation of the late-stage structures, including the cornified envelope (15) . It was further determined that KLF4 is required for terminal differentiation of goblet cells in the colon and that loss of KLF4 in mice causes altered proliferation and differentiation, as well as precancerous changes, in the adult stomach (16) , indicating that KLF4 plays a role in proliferation-differentiation switch. Loss of KLF4 might block terminal differentiation and therefore pave the way for unscheduled cellular proliferation which may be an important mechanism of tumor development (17) .
Cancer development contains multistep processes that can be divided both operationally and mechanistically into three phases: initiation, promotion and progression (18) . The pathways that specify epithelial cell fate during development appear to mediate these early steps for certain forms of carcinoma (19) (20) (21) (22) (23) (24) . Due to the role of proliferation-differentiation switch, KLF4 may possess a function like tumor suppressor. Indeed, it has been reported that KLF4 expression decreased in some human cancers including gastric, colorectal, bladder and prostate cancers. Downregulation of KLF4 in these cancers may contribute to cellular hyperproliferation and malignant transformation (25) (26) (27) . On the other hand, elevated KLF4 levels have also been linked to cancer. It was found that KLF4 is overexpressed in 70% mammary carcinomas and most squamous cell carcinomas of the oropharynx (24, 28) . Regarding skin cancer development, Foster et al. (24) reported that forced expression of KLF4 in basal keratinocytes initiates squamous epithelial dysplasia. However, another recent study suggests a tumor-suppressive role of KLF4 in a UVB-induced mouse skin tumor model (29) . Overall, the role of KLF4 in skin tumorigenesis remains controversial.
In this study, we showed that KLF4 expression was absent in most tumor samples (21/24) from patients with skin squamous cell carcinoma and basal cell carcinoma, suggesting a tumor-suppressive role of KLF4 in skin cancer development. Consistently, cell proliferation, migration and adhesion were increased when KLF4 was knocked down in a human epidermal squamous cell carcinoma SCC13 cell line, conclusion of which was confirmed by the opposite effects upon KLF4 overexpression in these cells. Finally, using our novel inducible KLF4 knockout mice coupled with a classical two-step 9, 10-dimethylbenz[a]anthracene (DMBA)/12-O-tetradecanoylphorbol-13-acetate (TPA) mouse skin tumor model, we found that tumor incidence and multiplicity were significantly enhanced upon KLF4 knockdown. Taken together, our data strongly support a tumorsuppressive role of KLF4 in skin cancer development. Cell culture and reagents Human squamous carcinoma cell line SCC13 was cultured in keratinocyte serum-free medium (K-sfm, Invitrogen) supplemented with 25 lg/ml bovine pituitary extract, 100 U/ml penicillin, 100 lg/ml streptomycin, 0.2 ng/ml epidermal growth factor, 0.3 mM CaCl 2 and 2 mM L-glutamine at 37°C in a humidified atmosphere of 5% CO 2 . Primary keratinocytes were isolated from 6-to 8-week-old mice and maintained in keratinocyte basal medium KBM-2 (Lonza, Walkersville, MD).
Materials and methods
Generation of KLF4-knockdown and -overexpression stable cell lines Plasmids containing KLF4-specific short hairpin RNA (pRetroSuper-KLF4#2) and the control vector (pRetroSuper) and KLF4 overexpression vector (pBabePuro-KLF4-N) and the control vector (pBabePuro) were kindly provided by Daniel S. Peeper (31) . pBabePuro-KLF4-N, expressed N-terminal 100 amino acid fragment of KLF4, can increase endogenous KLF4 expression by an unidentified mechanism. 1.6 lg plasmids were transfected into skin cancer cells using Lipofectamine TM 2000 (Invitrogen). Forty-eight hours after transfection, cells were trypsinized and reseeded onto 10 cm culture plates. Cells were selected with puromycin at a final concentration of 2 lg/ml. Single colonies were selected, confirmed by western blotting and expanded for further experiments.
RNA extraction and quantitative reverse transcription-PCR analysis Total RNA was prepared using Trizol Reagent (Invitrogen) according to the manufacturer's instructions. First-strand complementary DNA (cDNA) synthesis was performed using Oligo (dT) and Superscript III reverse transcriptase (Invitrogen). Real-time PCR was performed as described previously (32) . Quantitative real-time PCR primers were used as follows: KLF4: 5#-GAAATTCGCCCGCTCCGATGA-3# (sense) and 5#-CTGTGTGTTTGCGG TAGTGCC-3# (antisense); glyceraldehyde 3-phosphate dehydrogenase: 5#-TTCGACAGTCAGCCGCATCTTCTT-3# (sense) and 5#-CAGGCGCC-CAAYACGACCAAATC-3# (antisense).
Protein extraction and western blotting analysis
Total proteins from culture cells and mouse back skin primary cells with indicated treatments were prepared using RIPA buffer, and 50 lg of proteins were separated by 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis gel followed by western blotting analysis as described (32) . The antibodies used were an anti-KLF4 rabbit polyclonal antibody (1:1500, Genespin, Milano, Italy), an anti-p21 antibody (1:1000, Santa Cruz Biotechnology) and an anti-a-Tubulin antibody (1:1000, Santa Cruz Biotechnology). ) isolated from control (KLF4þ/þ) or KLF4 (�/�) mouse back skin were seeded onto 96-well tissue culture plates and incubated at 37°C in a humidified atmosphere of 5% CO 2 for 12 h, 1, 3 and 5 days, respectively. At the indicated time point, 3-(4,5-dimethylthiazole-2-yl)-2,5-bdiphenyl tetrazolium bromide (MTT) cell proliferation assay kit (ATCC, Manassas, VA) was used to detect absorbance at 570 nm according to the manufacturer's instructions.
Cell migration assay
Modified Boyden chamber assay was used to examine cell migration as reported (33) . Briefly, SCC13 cells (7 � 10 4 ) or primary keratinocytes (7 � 10 4 ) isolated from control (KLF4þ/þ) or KLF4 (�/�) mice were plated onto Transwell chambers (5 lm pore, Corning) coated with Type I collagen. K-sfm or KBM-2 media supplemented with 10% fetal bovine serum was added into the lower chamber. After incubation for 6 h, cells were fixed and stained with 0.1% crystal violet. Non-migrating cells on the upper membrane were removed with a cotton swab. Cells on the bottom surface of each membrane were counted (10-12 fields per well, triplicate for each experimental group) after incubation. Experiments were performed in triplicate.
Cell attachment assay 96-well tissue culture plates were coated with 20 lg/ml fibronectin at 37°C for 1 h and blocked with 5 mg/ml heat-denatured BSA (Sigma) for 1 h. SCC13 cells or primary keratinocytes (2 � 10 4 ) isolated from control (KLF4þ/þ) or KLF4 (�/�) mice were added to each well and cells were allowed to incubate at 37°C for 30 min. After washing twice, attached cells were fixed, washed, and stained with 0.1% (w/v) crystal violet for 10 min. The stained cells were washed thoroughly and dissolved in 2% sodium dodecyl sulfate, and absorbance at 550 nm was measured.
IHC analysis
Following sacrifice, mouse skin tissues were dissected, embedded in paraffin and sectioned at 4 lm. IHC was performed using a standard protocol. Signal was detected using the KPL's DAB Reagent Set (KPL, Gaithersburg, MD) according to the manufacturer's instructions, and counterstaining was carried out with Mayer hematoxylin. The following primary antibodies were used: rabbit anti-KLF4 polyclonal antibody (1:500, Genespin, Italy), rabbit antiKi67 antibody (1:500, Abcam).
Keratinocyte purification
Collection of mouse dorsal skin keratinocytes was performed as reported previously (34, 35) . Six-to eight-week-old female mice were killed, dorsal fur was clipped and dorsal skin was removed. All subcutaneous tissues from the skin were scraped, and the skin cut into 0.5 � 1 to 1.5 cm strips and incubated at 32°C in Dulbecco's phosphate-buffered saline with 0.25% trypsin without ethylenediaminetetraacetic acid for 2 h. The epidermis was then scraped into Harvesting Medium (SMEM with 10% fetal bovine serum; Invitrogen). After stirring at 100 r.p.m. on a magnetic stirrer for 20 min at room temperature, the suspension was filtered through a 70 lm cell strainer (BD Biosciences), and keratinocytes were counted using a hemacytometer.
Generation of the tamoxifen-inducible KLF4/CreER mouse model A construct containing Cre recombinase cDNA fused with a tamoxifen-inducible estrogen receptor (ER) gene (a plasmid kindly provided by Dr Douglas Melton at Harvard Medical School) was used as a PCR template to amplify a fragment containing tamoxifen-inducible CreER cDNA sequences and 5# and 3# ends homologous to sequences flanking the mouse tamoxifen-inducible CreER PCR primers: sense 5 GGTCCCTGTGCGCCCCGCCCGGCCCGCAGGCAGC-CACCTGGCGAGTCTGACATGTCCAATTTACTGACCGTACA, antisense 5 GGCCGGACGCGAACGTGGAGAAGGACGGGAGCAGAGCGTCGCT-GACAGCCATTCAGATCGTGTTGGGGAAGCCGTG, the underlined region is homologous to the sequence flanking the KLF4 translation start site. Bacterial artificial chromosome (BAC) clone # RP23-322L22 was obtained from Children's Hospital Oakland Research Institute (CHORI) and the BAC clone was then introduced into a bacterial strain BL250. BL250 bacteria containing RP23-322L22 were made competent and transformed with the amplified tamoxifen-inducible CreER fragment by electroporation according to a previous report (36) . Clones in which the amplified fragment was inserted via homologous recombination were selected using resistance to chloramphenicol and kanamycin. Selected colonies were screened for correct recombination by amplification using Cre-and KLF4-specific primers. The FRT-flanked KANA gene was excised from tamoxifen-inducible KLF4/CreER-KANA BAC clones by expressing the FLP recombinase. CHEF gel electrophoresis and DNA sequencing confirmed correct transgene constructions and integrity of the BAC flanking sequence. The tamoxifen-inducible KLF4/CreER BACs were then purified for pronuclear microinjection. Potential founder mice (B6/CBA mixed background) were genotyped by tail DNA amplification using primers specific for the Cre coding sequence. The founder transgenic mice were then backcrossed 6-8 generations to obtain the pure C57BL/6 background. Cre recombinase was induced by daily i. p. injection of tamoxifen (100 mg/kg) (Sigma) for five consecutive days.
Maintenance of mouse colonies and the classical DMBA/TPA mouse skin tumor model Mice were housed in micro-isolator solid-bottomed polycarbonate cages under a pathogen-free condition and experiments were approved by the Institutional Animal Care and Use Committees of University of South Carolina. Skin tumors were generated as described (18) . Briefly, the control and tamoxifeninduced KLF4/CreER and KLF4(floxþ/þ) double transgenic mice were treated with a single dose of DMBA (100 nmol/100 ll acetone; Sigma) followed by repetitive TPA applications (10 nmol/100 ll acetone: Sigma) twice a week for 26 weeks. Acetone-treated control mice (acetone/acetone, DMBA/acetone or acetone/TPA) used as internal controls and did not develop any tumors. Tumors were assessed weekly. Mice were killed 4 weeks after the final treatment. Generation of KLF4(floxþ/þ) mice has been described previously (37) .
Statistical analysis
Quantification of Ki-67-positive cells was performed using Image Pro Plus 5.1 software (Media Cybernetics, Bethesda, MD) on stained skin sections from at least three different samples and the average value was the percentage of Ki-67-positive cells. Two-way analysis of variance and two-tailed t-tests were employed to analyze the data using Prism 5.0 software (GraphPad). P , 0.05 was defined as statistically significant.
Results
Absence of KLF4 expression in patient samples of skin cancer Recent studies have shown that KLF4 functions either as a tumor suppressor or an oncogene depending on different cellular contexts (17) . In order to determine the role of KLF4 in skin tumor development, we analyzed KLF4 expression in 24 formalin-fixed paraffin-embedded human skin tumor samples (12 patients with squamous cell carcinoma and 12 with basal cell carcinoma) and 24 human cancer adjacent normal dermatic tissues. The numbers of female and male patients were the same. As shown in Table I , in squamous cell carcinoma, the lesions included tempus, thigh, face and scalp. Seven cases were malignant grade 1 and the remaining was malignant grade 2 (data not shown). In basal cell carcinoma, lesions were located in eyelids, pars zygomatica, face, nasal ala, corona capitis and frontal region. As expected, KLF4 was expressed in the epithelial cells of 24 normal skin tissue samples but only expressed in 3 of 24 tumor samples detected by immunohistochemical staining. Strong KLF4 staining was observed in the suprabasal layer (arrows in inset) with diffused staining in basal layers in normal tissue (Supplementary Figure 1B is available at Carcinogenesis Online). Typical KLF4 expression patterns of cancer samples (middle and right panels) were shown in Supplementary Figure 1A (available at Carcinogenesis Online). Absence of KLF4 staining in 87.5% (21 in 24 samples) skin tumor samples supports a tumor-suppressive role of KLF4 in skin cancer development.
KLF4 inhibits proliferation and migration of human epithelial carcinoma SCC13 cells
To test the function of KLF4 in cell proliferation in vitro, we generated KLF4-knockdown stable cells (designated as shKLF4) by transduction with an established KLF4-specific short hairpin RNA vector (31) and KLF4-overexpressing stable cells (designated as KLF4-N) by transduction with an N-terminal version of KLF4 in human epidermal squamous carcinoma cell line SCC13 and in epidermoid carcinoma cell line A431. Note that the full-length KLF4 was not used because of its strong antiproliferative effect and very few stable colonies obtained in the establishment of stable cells. Quantitative real-time PCR analysis and western blot analysis ( Figure 1A ) confirmed the expected levels of KLF4 messenger RNA and protein in KLF4-knockdown and -overexpressing stable SCC13 cells. To test whether KLF4 has an effect on cell proliferation in SCC13 cells, we performed the MTT assay in KLF4 knockdown and overexpression cells. As expected (38) , cell proliferation was significantly accelerated after KLF4 knockdown ( Figure 1B ). Consistently decreased proliferation was observed upon KLF4 overexpression ( Figure 1C ). The same results were obtained in A431 cells after KLF4 knockdown and overexpression (Supplementary Figure 2B is available at Carcinogenesis Online and data not shown). Mechanistically, previous work determined that KLF4-mediated G 1 arrest was via transcriptional induction of p21 (38) . In our study, p21 protein levels were indeed decreased in shKLF4 cells when compared with that in control cells as shown in Figure 1A . Consistently, increased p21 protein levels were observed in KLF4-overexpressing cells ( Figure 1A ). Our data thus support that KLF4 inhibits tumor cell proliferation at least in part through a p21-dependent manner.
One of the important properties of tumor cells is their increased mobility. To evaluate whether KLF4 regulates cell migration, we performed a transwell assay using KLF4 knockdown and overexpression cells. As shown in Figure 1D , the number of migrated shKLF4 cells had a 1.41-fold increase when compared with that of the shCon cells. Consistently, the number of migrated KLF4-overexpressing cells was 55% less than that of the control cells. In addition, it is well established that cell attachment or detachment with the matrix where the tumor grows in the microenvironment is the 'hallmark' of cell migration and invasion during metastatic processes (39) . Notably, the shKLF4 cells had increased capacity of attachment with fibronectin when compared with the shCon cells, and consistently KLF4-overexpressing cells showed decreased adhesion when compared with the control cells ( Figure 1E ), indicating that KLF4 has an inhibitory effect on cell adhesion.
Generation of an inducible KLF4 knockout mouse model Full KLF4 knockout mice die shortly after birth due to dehydration which partially prevents us from studying the role of KLF4 in adult (15) . To circumvent this situation and to study the in vivo function of KLF4, we first generated tamoxifen-inducible KLF4/CreER transgenic mouse model using a Cre recombinase as the transgene derived from a mouse KLF4 gene-containing BAC (RP23-322L22) (36) . This BAC clone contains �119kb 5# and 82kb 3# fragments of KLF4 gene. In this transgene, a Cre recombinase cDNA fused with a tamoxifeninducible (TM) ER (CreER TM ) gene was precisely inserted into the KLF4 locus at the initiating methionine without deleting any endogenous KLF4 sequences, so that CreER TM gene expression was under the control of a big 5# sequence of the KLF4 gene. A diagram of the construction strategy to generate a KLF4/CreER TM transgene was shown in Figure 2A . Western blot confirmed the expression of Cre at a protein level and its expression did not influence that of the endogenous KLF4 ( Figure 2B) . Fidelity of the model was also confirmed by matched expression patterns of Cre with that of endogenous KLF4 by IHC in mouse small intestine and colon (data not shown). Then, these mice were crossed with KLF4(floxþ/þ) mice (37) to generate tamoxifen-inducible KLF4/CreER (þ/�) and KLF4(floxþ/þ) double transgenic mice and KLF4 was knocked out by daily tamoxifen i. p. injection at a dose of 100 mg/kg for five consecutive days. As shown in Figure 2C (high magnification in Supplementary Figure 3C is available at Carcinogenesis Online), while KLF4 staining indicated by red arrows (left) was abundant in hair follicles of the mice induced with vehicle control, the staining was almost absent in hair follicles of mice with tamoxifen induction (right), suggesting a successful KLF4 knockout in our KLF4-inducible knockout model. Western blotting analysis also confirmed the drastically reduced protein levels of KLF4 in skin keratinocytes after tamoxifen induction when compared with that after the control induction ( Figure 2D ).
KLF4 deficiency is accompanied by increased cell proliferation in vivo
Eight weeks after induction of tamoxifen-inducible KLF4/CreER (þ/�) and KLF4(floxþ/þ) double transgenic mice with tamoxifen, no obvious phenotypic changes of mouse hairs were observed. However, number of the hair follicles was prominently increased upon KLF4 knockout as indicated by the arrows in Supplementary Figure 4A is available at Carcinogenesis Online when compared to that in the control by hematoxylin and eosin staining, which was consistent with an inhibitory function of KLF4 in proliferation in vitro. In addition, changes of suprabasal cells from a single layer to multiple layers in KLF4 knockout mice was also observed (insets in Figure 3A and Supplementary Figure 4B) , suggesting a high proliferative status of these cells upon KLF4 knockout. The total number of keratinocytes purified from 3 Â 3 cm 2 back skin was increased from 1.81 Â 10 7 ± 1.15 Â 10 6 in control mice to 2.77 Â 10 7 ± 7.02 Â 10 5 in KLF4 knockout mice ( Figure 3B ). Consistently, IHC staining with the proliferation marker Ki67 in skin tissue also confirmed the increased proliferation of hair follicles upon KLF4 knockout. As shown in Figure 3C and D and Supplementary Figure 4D (available at Carcinogenesis Online), the proportion of Ki67-positive cells increased from 8% to 43% after KLF4 knockout. These results indicate that deficiency of KLF4 is accompanied by increased cell proliferation of mouse skin keratinocytes.
KLF4 inhibits migration and adhesion of mouse primary keratinocytes ex vivo
Our previous study showed increased proliferation status of keratinocytes from the dorsal skin of KLF4 knockout mice. Using purified keratinocytes from the control and KLF4 knockout mouse back skin, we performed the MTT assay to further examine the cell proliferation ex vivo. As expected, the cell proliferation was significantly accelerated upon KLF4 knockout ( Figure 4A ). Next, we evaluated whether KLF4 regulates cell migration and adhesion ex vivo by the transwell assay. As shown in Figure 4B , the number of migrated cells purified from KLF4 knockout mice was increased 1.53-fold when compared with that from the control mice. Similar results were obtained when the transwell chambers were coated with Type I collagen ( Figure 4C ), an assay for cell invasion, indicating that KLF4 inhibits both migration and invasion of primary mouse skin keratinocytes. Furthermore, in an attachment assay, KLF4 knockout keratinocytes exhibited an 80% increase of cell attachment to fibronectin when compared with the control keratinocytes ( Figure 4D ). Taken together, these results suggest that KLF4 inhibits cell migration and adhesion of mouse primary keratinocytes.
KLF4 deficiency is accompanied by the enhanced skin tumorigenesis in a DMBA/TPA mouse skin cancer model We have shown that KLF4 knockdown was associated with increased proliferation of cells of skin squamous cell carcinoma ( Figure 1 ) and knockout of KLF4 increased proliferation of primary mouse skin (E) KLF4 inhibited cell adhesion capacity as measured by an attachment assay. SCC13 cells were plated into a 96-well plate treated with fibronectin at a density of 2 Â 10 3 cells per well in triplicate. Cells were allowed to adhere for 2 h and adherent cells were stained with crystal violet and quantified using the absorbance as a measurement at 550 nm.
Ã P , 0.05 versus control. mRNA, messenger RNA.
keratinocytes (Figures 3 and 4) , suggesting a tumor-suppressive role of KLF4 in skin cancer development. To test this hypothesis, we utilized a classical two-step DMBA/TPA mouse skin cancer model. Five pairs of tamoxifen-inducible KLF4/CreER(þ/�)/KLF4(floxþ/þ) double transgenic female mice at 4-week-old were i. p. injected with vehicle (KLF4þ/þ mice) or tamoxifen (KLF4�/� mice) to induce KLF4 knockout. They were then treated with a single topical application with the carcinogen DMBA (100 nmol/100 ll acetone), followed by promotion with the phorbol ester TPA (10 nmol/100 ll acetone) for 26 weeks (18) . Tumors were found on KLF4�/� back skin after 12 weeks of promotion and by 30 weeks 80% percent KLF4�/� mice had developed tumors. In contrast, control mice developed tumors after 15 weeks and the tumor incidence was 20% ( Figure 5A , left). Tumor multiplicity in KLF4�/� mice was two tumors per mouse but only 0.6 tumors per mouse in control mice ( Figure 5A, right) . Moreover, tumor size in control mice was smaller ( Figure 5B ). Highly differentiated and hyperkeratotic morphology was shown in KLF4�/� tumor by hematoxylin and eosin staining ( Figure 5C ). The accelerated incidence and increased multiplicity of mouse skin tumors in KLF4 knockout mice strongly support a tumor-suppressive role of KLF4 in the DMBA/TPA mouse skin tumor model.
Discussion
KLF4 has been thoroughly investigated in cell cycle arrest and cellular differentiation. Loss of KLF4 in mice caused altered proliferation in adult colon and stomach (25, 27) . Here, using our tamoxifen-inducible KLF4 knockout mouse model and stable cancer cells, we showed that KLF4 deficiency promotes cell proliferation which is consistent with the function of KLF4 in cell cycle arrest. Previous studies have shown that KLF4 is required for the terminal differentiation of skin epidermal cells as wells as goblet cells in the colon (15, 16) . Given the importance of KLF4 in proliferation-differentiation switch (16), our current results are consistent with the hypothesis that KLF4 deficiency might block differentiation resulting in enhanced cell proliferation (17) and support a tumor-suppressive role of KLF4 in skin carcinogenesis. Earlier studies have shown that KLF4 functions either as a tumor suppressor or an oncogene (17) . Our current results are consistent with a tumor-suppressive role of KLF4 in skin cancer development, which is supported by a recent report showing that KLF4 expression was substantially decreased in UVB-induced murine skin tumors (29) . However, our results are not entirely consistent with the report by (24) indicating that increased KLF4 expression in basal keratinocytes initiates squamous epithelial dysplasia. Different systems may be a major factor that contributes to this discrepancy. In our study, we used the classical DMBA/TPA mouse skin tumor model with systemic KLF4 knockout, but in the published paper, the investigators used a transgenic approach in which KLF4 was overexpressed in mouse basal keratinocytes. Given the initiation and progression nature of tumorigenesis, KLF4-overexpressing transgenic mouse models may not be able to separate these two steps, which may complicate the interpretation of the observations (more discussions in the next paragraph). Nevertheless, in our study, 21 of 24 tumor samples of squamous cell carcinoma and basal cell carcinoma lost KLF4 staining by IHC, which is consistent with the results from the previous study showing that 3 of 5 squamous cell carcinomas and basal cell carcinomas had little or no KLF4 staining (24) . In addition, KLF4 expression examined by immuohistochemistry may also depend on subtype and the specific stage of the skin tumor samples, which may be the other factors contributing to discrepancies of the final conclusions. Furthermore, different functions of KLF4 may be derived from different isoforms of KLF4 expressed in the tissue. For example, while KLF4 is generally KLF4 inhibits skin tumorigenesis considered as a tumor suppressor in pancreatic cancer development (40) , upregulation of KLF4a, one of the KLF4 isoforms, was observed in aggressive pancreatic cancer cells and human pancreatic tumor tissues. This KLF4 isoform promotes growth of pancreatic tumors in mice and is associated with reduced survival times of patients (41) . It is currently unknown whether different KLF4 isoforms exist in skin that may have different functions. Nevertheless, available data suggest that KLF4 has a complicated role in cancer development, and clearly more well-defined studies are needed to fully elucidate how KLF4 functions in tumorigenesis.
In the current study, we generated an inducible KLF4 knockout mouse model by crossing our new tamoxifen-inducible KLF4/CreER mice with established KLF4(floxþ/þ) mice. This unique model allowed us to study the function of KLF4 in adult mice upon tamoxifen induction because KLF4 full knockout mice die of dehydration shortly after birth (15) . In addition, we can use this model to time KLF4 knockout before or after tumor initiation, which is necessary to separate the function of KLF4 in tumor initiation and progression including metastasis. In this study, we induced tamoxifen-inducible KLF4/ CreER(þ/�) and KLF4(floxþ/þ) double transgenic mice with tamoxifen before DMBA/TPA treatment and found that KLF4 deficiency was accompanied by increased skin tumorigenesis, suggesting that KLF4 inhibits tumor initiation. Alternatively, early expansion of the bulge stem cells is blocked by KLF4 knockout resulting in the increased number of tumors, which is supported by the requirement of KLF4 for the maintenance of cancer stem cells (14) . It has been reported that KLF4 deficiency in the mouse esophagus is correlated with incidence of esophageal squamous cell carcinoma and delayed differentiation (42) . However, overexpression of KLF4 in mouse esophagus activates inflammation-mediated esophageal squamous cell cancer (43) . These observations are consistent with the hypothesis that KLF4 has different functions at different stages of cancer development. Thus, it will be interesting to know the outcome if we knockout KLF4 after DMBA/ TPA treatment in our mouse model. We would expect that KLF4 may function as a tumor promoter after tumor initiation, not only because of its role in inflammation (44, 45) that is a critical component of carcinogenesis (46) but also its requirement for maintenance of cancer stem cells (14) . It is interesting to note that control and KLF4�/� mice showed fewer numbers of tumors per mice when compared with that published before (18) . An exact reason is currently unknown. Possible explanations for this discrepancy include genetic background of the mice and the batch of carcinogen DMBA and TPA. Our KLF4/Cre mice were originally created in a mixed background (CBA/C57BL/ 6J) and have been backcrossed with the wild-type C57BL/6J mice that do not carry Ha-Ras mutations (47) . It is known that DMBA-induced mutations in Ha-Ras can be found in the earliest detectible lesions (48) . Therefore, it will be interesting to examine Ha-Ras mutations in our KLF4 knockout mouse model in order to delineate mechanisms of skin tumorigenesis. In addition, similar to in vitro studies ( Figure 1A) , Fig. 4 . KLF4 deficiency is accompanied by increased cell proliferation, migration and adhesion in mouse primary skin keratinocytes. Primary back skin keratinocytes were isolated from control (KLF4þ/þ) and KLF4 knockout (KLF4�/�) mice. (A) The MTT assay was performed to detect cell proliferation. Five thousand cells were seeded into a 96-well plate. At day 0, 1, 3, 5, absorbance at 550 nm was measured. Values were expressed as mean ± SM of three independent experiments. � P , 0.05 versus control. Primary keratinocytes (7 � 10 4 ) were plated onto transwell chambers without (B) or with Type I collagen coating (C). KBM-2 media supplemented with 10% fetal bovine serum were added into the lower chamber. After incubation for 6 h, cells were fixed and stained with 0.1% crystal violet. Migrated cells were counted (10 to 12 fields per well, triplicate for each experimental group) after incubation. Values were expressed as mean ± SM of three independent experiments. � P , 0.05 versus control. (D) The cell attachment assay was performed to detect adhesion capacity upon KLF4 knockout. Primary mouse skin keratinocytes were plated into a 96-well plate coated with fibronectin at a density of 2 � 10 3 cells per well in triplicate. Cells were allowed to adhere for 2 h and adherent cells were stained with crystal violet and quantified using the absorbance as a measurement at 550 nm.
� P , 0.05 versus control. SM, standard mean. expression of p21 was significantly reduced in the tumor derived from KLF4 knockout mice when compared with that from wild-type mice (Supplementary Figure 5 is available at Carcinogenesis Online). These results suggest involvement of the DNA repairing pathway in which p21 plays a key role (49) . KLF4 has been reported to regulate or associate with urokinase-type plasminogen activator receptor (u-PAR) and laminin-5, which play critical roles in cell migration, growth and invasion (30, 50, 51) . Overexpression of KLF4 in colon cancer cells suppresses tumorigenesis by potently inhibiting colony formation, cell migration and adhesion (52) . These observations demonstrate that KLF4 plays a role in the regulation of cell motility, such as cellular migration and invasion, which are contributing factors of tumorigenesis (53) . Consistently, in our studies, knockout of KLF4 in mouse primary keratinocytes is accompanied by increased cell migration and adhesion. The same trend was observed by using the KLF4-knockdown and -overexpression SCC13 cells, indicating that KLF4 has a critical function in regulating cell mobility. These results may provide clues to additional mechanisms by which KLF4 inhibits skin carcinogenesis. 
